Clinical Trial Update: Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer [Phase 1, Phase 2]

View source ↗

Summary

This document reports the completion of Phase 1/Phase 2 clinical trials evaluating an HLA-A*2402-restricted peptide vaccine for gastric cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• HLA-A*2402 Restricted Peptide Vaccine Therapy

Snippet

Sponsor: Tokyo University | Conditions: Gastric Cancer | Phase 1, Phase 2 | Status: COMPLETED